Samya Aouad

Ms. Samya Aouad

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
Ana Lilia Moreno SalinasAna Lilia Moreno Salinas
Ana Lilia Moreno Salinas
AMArturo Mancini
Arturo Mancini
SASamya Aouad
Samya Aouad
HKHerthana Kandasamy
Herthana Kandasamy
SMSandra Morissette
Sandra Morissette
Laurent SabbaghLaurent Sabbagh
Laurent Sabbagh
The adhesion G protein-coupled receptor ADGRE5/CD97 is upregulated in many cancers, representing a potential drug target in oncology/immuno-oncology. Yet, ADGRE5′s activation and signaling mechanisms remain poorly understood. Here, we used enhanced bystander bioluminescence resonance energy transfer (ebBRET)-based biosensors and three strategies to characterize human (h) ADGRE5 signaling. First, a synthetic tobacco etch virus (TEV) protease-cleavable receptor chimera enabling controlled tethered agonist (TA) exposure at the GPCR proteolysis site (GPS) revealed signaling through Gα12 and Gα13, along with the recruitment of β-Arrestins 1/2 (β-Arrs). Second, we investigated WT hADGRE5 signaling elicited by Gingipain K (Kgp), an endopeptidase that cleaves hADGRE5 upstream of the GAIN domain. Kgp mirrored TEV-induced signaling but also promoted Gαz and Gα11 activity. The abolition of hADGRE5′s GPS did not block Kgp-induced receptor activation, revealing a GPS cleavage-independent mechanism of action. Finally, we developed an assay to study hADGRE5 mechanical stimulation (MS) using β-Arr2 as a readout. MS promoted β-Arr2 recruitment in hADGRE5-expressing cells, and this response was lost upon abolition of the GPS. A neutralizing antibody to the hADGRE5 ligand CD55 significantly dampened MS-induced β-Arr2 engagement. Overall, this study advances our understanding of hADGRE5′s signaling and highlights the receptor’s plasticity in activating pathways via both GPS cleavage-dependent and -independent mechanisms.

3 April 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
SASamya Aouad
Samya Aouad
MKMaleck Kadiri
Maleck Kadiri
DADavid Allard
David Allard
ESEmma Skora
Emma Skora
LGLucie Giraud
Lucie Giraud
John StaggJohn Stagg
John Stagg
Background: Identifying the mechanisms underlying resistance to immune checkpoint inhibitors (ICIs) has become a major focus in cancer immunotherapy. Our previous work identified F2RL1 expression, encoding the G protein-coupled receptor Protease-Activated Receptor-2 (PAR-2), as a negative biomarker of ICIs responsiveness. This study aims to evaluate the therapeutic potential of targeting PAR-2 to overcome resistance to ICIs. Methods: Activated PAR-2 levels in patient serum were quantified using a protein-based assay to assess PAR-2 activation and its association with clinical outcomes. The therapeutic impact of PAR-2 targeting was evaluated in preclinical tumor models using either global F2rl1 gene deletion or pharmacological inhibition with the selective, insurmountable PAR-2 negative allosteric modulator I-117, in combination with anti-PD-1 therapy. To further characterize immune changes associated with PAR-2 targeting, immune cell populations, cytokine profiles, and transcriptional programs were analyzed in tumors and/or tumor-draining lymph nodes (tDLNs). Ex vivo co-culture assays were performed to assess antigen presentation by CD11c + dendritic cells. Results: Activated PAR-2 levels were significantly elevated in the serum of patients with cancer across multiple tumor types and were associated with reduced survival in patients with lung cancer treated with pembrolizumab plus platinum-based chemotherapy. In preclinical models, both global F2rl1 deletion and pharmacological inhibition of PAR-2 with I-117 significantly potentiated the therapeutic efficacy of anti-PD-1 treatment. PAR-2 inhibition altered the tumor immune microenvironment, characterized by a reduction in putative immunosuppressive myeloid cell populations and increased activation of CD8 + T cells in tumors and tDLNs. These immune changes were accompanied by a cytokine shift favoring T helper 1 (Th1)-type responses and reduced immunosuppressive cytokines. Bulk RNA sequencing of myeloid cells indicated that PAR-2 activity was associated with impaired antigen presentation pathways. Consistently, ex vivo co-culture assays demonstrated that antigen-presenting functions of tumor-associated and draining lymph node CD11c + dendritic cells were significantly enhanced following PAR-2 inhibition with I-117. Conclusions: These findings support PAR-2 inhibition as a strategy to enhance the efficacy of PD-1 blockade, providing a rationale for their combined use in cancer immunotherapy.

18 May 2023 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
AMArturo Mancini
Arturo Mancini
SASamya Aouad
Samya Aouad
HKHerthana Kandasamy
Herthana Kandasamy
RCRobert Cerone
Robert Cerone
SSStephan Schann
Stephan Schann
Laurent SabbaghLaurent Sabbagh
Laurent Sabbagh
ID 14943 Poster Board 485 ADGRE5 is a prototypical adhesion GPCR (aGPCR) that is expressed mainly on T lymphocytes, monocytes/macrophages, granulocytes, NK cells (especially CD56bright) and smooth muscle cells. Importantly, ADGRE5 expression is upregulated in many cancers (e.g., gastric/colorectal/pancreatic carcinomas, various leukemias, glioblastoma), whereas the corresponding normal tissues express relatively little or no ADGRE5. Previous studies indicated that ADGRE5 plays an important role in modulating cell adherence/detaching, migration, invasion, and metastasis, making ADGRE5 a potential drug target in oncology/immuno-oncology. Yet, the development of assays enabling the discovery of drugs acting on aGPCRs has been complicated by the lack of functional agonists and the complex multimodal mechanisms believed to govern receptor activation. Current methods rely on artificial methods of activation that preclude the identification of allosteric modulators acting upon ADGRE5’s tractable long extracellular N-terminal fragment. We describe a novel in vitro enhanced bystander (eb)BRET-based assay allowing to detect the activity of the full-length (native) form of human (h)ADGRE5 via its physiological activation mode (i.e., following mechanical stimulation (MS)). Indeed, subjecting full-length hADGRE5 isoform1- or isoform2-transfected HEK293 to vigorous orbital shaking resulted in a rapid time-dependent recruitment of ssArrestin 2 (ssArr2) to the plasma membrane. Such mechanosensitivity was not observed with a control receptor (mu opioid receptor), despite its ability to engage ssArr2 following ligand stimulation. Interestingly, MS-induced ssArr2 engagement was absent with hADGRE5 harboring a mutated GPCR proteolysis site (GPS), which is believed to play an important role in aGPCR activation through the exposure of a tethered agonist following cleavage. Lack of activity was not related to defective cell surface expression of the GPS mutant, as both WT and GPS mutant forms of hADGRE5 displayed comparable surface expression when evaluated by flow cytometry. Similarly, MS provoked a delayed internalization of WT hADGRE5 but not that of the GPS mutant. CD55/DAF is one of four ligands described to interact with hADGRE5’s adhesive EGF-like folds and has been shown to promote MS-dependent downregulation of leukocyte ADGRE5 in vivo. We showed that CD55/DAF is expressed endogenously by HEK293, leading us to hypothesize that trans-signaling complexes between CD55/DAF and hADGRE5 could mediate the hADGRE5 activity observed in our MS assays. Indeed, addition of a neutralizing anti-CD55 antibody significantly dampened MS-induced hADGRE5 ssArr2 recruitment. Finally, the robustness of the MS ssArr2 recruitment assay was evaluated in 96-well plates and resulted in a Z’ = 0.73, thus rendering this assay compatible for high-throughput screening of compound libraries. Collectively, our ebBRET-based assay is robust and will help identify and characterize novel therapeutic agents acting on (patho)physiologically relevant mechanisms of ADGRE5 activation through both orthosteric and allosteric receptor sites.